Patents Examined by Amanda L Aguirre
  • Patent number: 10464894
    Abstract: The present disclosure provides conjugate structures and hydrazinyl-pyrrolo compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: November 5, 2019
    Assignee: Redwood Biosciences, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Romas Alvydas Kudirka, Albert W. Garofalo
  • Patent number: 10464874
    Abstract: The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to compositions comprising these compounds.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: November 5, 2019
    Assignee: Merck Patent GmbH
    Inventors: Reiner Friedrich, Julian Osthoff
  • Patent number: 10450309
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: October 22, 2019
    Assignee: Merch Sharp & Dohme Corp.
    Inventors: Yongxin Han, Satyanarayana Tummanapalli, Phieng Siliphaivanh, Kerrie Spencer
  • Patent number: 10442771
    Abstract: The present invention is directed to systems, devices and methods for identifying biopolymers, such as strands of DNA, as they pass through a constriction such as a carbon nanotube nanopore. More particularly, the invention is directed to such systems, devices and methods in which a newly translocated portion of the biopolymer forms a temporary electrical circuit between the nanotube nanopore and a second electrode, which may also be a nanotube. Further, the invention is directed to such systems, devices and methods in which the constriction is provided with a functionalized unit which, together with a newly translocated portion of the biopolymer, forms a temporary electrical circuit that can be used to characterize that portion of the biopolymer.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: October 15, 2019
    Assignee: ARIZONA BOARD OF REGENTS on behalf of ARIZONA STATE UNIVERSITY
    Inventors: Stuart Lindsay, Peiming Zhang
  • Patent number: 10421696
    Abstract: This invention provides enantioenriched Mannich adducts with quaternary stereogenic centers and novel methods of preparing the compounds. Methods include the method for the preparation of a compound of formula (I): comprising treating a compound of formula (II): with a transition metal catalyst under alkylation conditions.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: September 24, 2019
    Assignee: California Institute of Technology
    Inventors: Brian M. Stoltz, Yoshitaka Numajiri, Beau P. Pritchett, Koji Chiyoda
  • Patent number: 10421763
    Abstract: The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: September 24, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Jay Jie-Qiang Wu, Ling Wang
  • Patent number: 10411200
    Abstract: A compound having the formula Ir(LA)n(LB)3-n is disclosed wherein LA is an aza-DBF ligand and LB is an alkyl-substituted phenylpyridine ligand, wherein the compound has a structure according to Formula I: wherein A1, A2, A3, A4, A5, A6, A7, and A8 comprise carbon or nitrogen; wherein at least one of A1, A2, A3, A4, A5, A6, A7, and A8 is nitrogen; wherein ring B is bonded to ring A through a C—C bond; wherein the iridium is bonded to ring A through a Ir—C bond; wherein X is O, S, or Se; wherein R1 and R2 each independently represent mono-, di-, tri-, tetra-substitution, or no substitution; wherein R? and R? each independently represent mono-, di-substitution, or no substitution; wherein any adjacent substitutions in R?, R?, R1, R2, R3, R4, R5, and R6 are optionally linked together to form a ring; wherein R1, R2, R?, and R? are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl,
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: September 10, 2019
    Assignee: UNIVERSAL DISPLAY CORPORATION
    Inventors: Bin Ma, Walter Yeager, Edward Barron, Alan Deangelis, Chuanjun Xia, Vadim Adamovich, Scott Beers, Harvey Wendt, Suman Layek
  • Patent number: 10392476
    Abstract: A polymer having a backbone of alternating N atoms and aromatic or heteroaromatic groups including a repeating structure of formula (I) wherein: R3 independently in each occurrence is a substituent; m is 0 or a positive integer; Ar1 and Ar2 are an aryl or heteroaryl group and at least one group selected from Ar1 and Ar2 has formula (II) wherein: each x is independently 0 or a positive integer; each y is independently 0 or a positive integer, and R1 and R2 independently in each occurrence is a substituent.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: August 27, 2019
    Assignees: Cambridge Display Technology Limited, Sumitomo Chemical Company Limited
    Inventors: Kiran Kamtekar, Ruth Pegington
  • Patent number: 10396287
    Abstract: An organic electronic device comprising an anode, a cathode, a semiconducting layer between the anode and the cathode and a hole transporting layer between the anode and the semiconducting layer, the hole-transporting layer comprising a co-polymer comprising repeat units of formula (I) and one or more co-repeat units: (I) wherein: Ar1 independently in each occurrence represents a fused aryl or fused heteroaryl group that may be unsubstituted or substituted with one or more substituents; Ar2 represents an aryl or heteroaryl group that may be unsubstituted or substituted with one or more substituents; R independently in each occurrence represents a substituent; and m is 1 or 2, preferably 1; and each Ar1 is directly bound to an aromatic or heteroaromatic group of a co-repeat unit.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: August 27, 2019
    Assignees: Sumitomo Chemical Company Limited, Cambridge Display Technology Limited
    Inventors: Jonathan Pillow, Richard J. Wilson, Sophie Barbara Heidenhain, Ruth Pegington, Alexander Doust, Richard Owoare
  • Patent number: 10393752
    Abstract: Provided herein is synthesis of novel mass spectrometry-cleavable cross-linking agents. The novel mass spectrometry-cleavable cross-linking agents can be used in mass spectrometry, tandem mass spectrometry, and multi-stage tandem mass spectrometry to facilitate structural analysis of intra-protein interactions in proteins and inter-protein interactions in protein complexes. Also provided are methods of mapping intra-protein interactions in proteins and inter-protein interactions in protein complexes.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: August 27, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Scott D. Rychnovsky, Lan Huang
  • Patent number: 10383850
    Abstract: The present invention provides compounds of formula (I), wherein A1, A2, Z1, Z2, Z3, R1, R2, R3, R4, R5, R6, n, p and q are as defined herein. In certain embodiments, the compounds of the invention are ROR?t antagonists. In other embodiments, the compounds of the invention are useful in the treatment and/or prevention of inflammatory and autoimmune conditions.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: August 20, 2019
    Assignee: ORCA PHARMACEUTICALS LIMITED
    Inventors: Clive McCarthy, Naomi Went, Roine Inge Olsson
  • Patent number: 10385044
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as “BHBA compounds”), which, inter alia, are (selective) retinoic acid receptor beta (RAR?) (e.g., RAR?2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR? (e.g., RARP?2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR? (e.g., RAR?2), that are ameliorated by the activation of RAR? (e.g., RAR?2), etc., including, e.g., neurological injuries such as spinal cord injuries.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: August 20, 2019
    Assignee: King's College London
    Inventors: Alan David Borthwick, Mark Trevor Mills, Jane Theresa Brown, Jonathan Patrick Thomas Corcoran, Maria Beatriz De Castro Vasconcelos Goncalves, Sarkis Barret Kalindjian
  • Patent number: 10370360
    Abstract: Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: August 6, 2019
    Assignees: The Board of Regents of the University of Texas System, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
    Inventors: Rolf A. Brekken, Ke Ding, Xiaomei Ren, Zhengchao Tu, Zhen Wang, Kristina Y. Aguilera
  • Patent number: 10363247
    Abstract: The invention generally relates to substituted benzofuranyl compounds and, more particularly, to a compound represented by Structural Formula 1a: (I) or a pharmaceutically acceptable salt thereof. The invention also includes the synthesis and use of the compound of Structural Formula 1a, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of diseases or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: July 30, 2019
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, William Senapedis
  • Patent number: 10364227
    Abstract: Compounds of formula (I) and salts are disclosed. Also disclosed are isotopes of compounds of formula I of the salts thereof. Pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using a compound of formula I are disclosed.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: July 30, 2019
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Sidney Hecht, Omar Khdour, Mohammad Alam, Sriloy Dey, Yana Chen, Arnaud Chevalier
  • Patent number: 10364250
    Abstract: Congener of portimine of the structure: where: R1 is selected from H, acyl, alkyl, alkylene, aryl and aralkyl; R2 is selected from H, acyl, alkyl, alkylene, aryl and aralkyl; M is O, S, N—NH2, N(alkyl)2, N-alkoxy or N(aryl)2; W and X may form a bond, an epoxide, or are independently selected from H, halogen, OH and O-acyl. Y and Z form a bond, an epoxide, or are independently selected from H, halogen (X), OH and O-acyl; and R1 and R2 are not H, M is not O, or W and X or Y and Z do not form a bond.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: July 30, 2019
    Inventors: Mark Barry Hampton, Andrew Ian Selwood, Feng Shi
  • Patent number: 10358405
    Abstract: The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: July 23, 2019
    Assignees: UNIVERSITY OF SOUTH FLORIDA, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Chad Dickey, Umesh Jinwal, Laurent Calcul, Bill J. Baker, Matthew Lebar
  • Patent number: 10351552
    Abstract: The invention is directed to a compound of formula I, a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing a compound of formula I, and a method of treatment of a disorder or condition in a mammal, including a human, selected from the group consisting of Human African Trypanosomiasis (HAT), Chagas disease, Leishmaniasis, toxoplasmosis and malaria.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: July 16, 2019
    Assignee: MediSynergies, LLC
    Inventors: Harry Ralph Howard, Dennis Michael Godek, Shawn-Michael Rodriguez
  • Patent number: 10350184
    Abstract: This invention relates to oxime and alkoxy derivatives of the general formula (I), or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and/or prevention of muscle atrophy in mammals and/or for limiting muscular atrophy in mammals and/or to promote muscle growth in exercising mammals aimed at increasing muscle mass and quality, preventing the occurrence of symptoms of sarcopenia related to age or rehabilitation after a muscle loss, age-related muscle atrophy and/or the consequences of drug therapy and/or immobilization and/or cachexia.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: July 16, 2019
    Assignee: METABRAIN RESEARCH
    Inventors: Sophie N. Raynal, Micheline R. Kergoat, Valerie Autier, Christine G. Charon, Jean-Denis Durand, Franck F. Lepifre, Annick M. Audet
  • Patent number: 10351519
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing CNS disorders containing a sulfamate derivative compound and/or pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a method for treatment or prevention CNS disorders comprising administering a sulfamate derivative compound in a pharmaceutically effective amount to a subject in need of treatment or prevention of CNS disorders.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: July 16, 2019
    Assignee: BIO-PHARM SOLUTIONS CO., LTD.
    Inventor: Yong Moon Choi